Listed company aims to become the European gateway for Asian pharmaceutical giants
Szeged, April 29, 2026 – Goodwill Pharma Plc., which debuted last year in the Standard category of the Budapest Stock Exchange (BSE), has closed the strongest financial year in its history. The Szeged-based pharmaceutical company recorded nearly HUF 23 billion in revenue in 2025, representing a 30% year-on-year increase and a new all-time high.
Closing an outstanding year marked by an EBITDA margin exceeding 27%, the General Meeting approved a dividend payment of HUF 1 billion. The robust growth was driven by both the expansion of manufacturing capacity in Szeged and a significant brand licensing transaction in the Balkan region.
Looking ahead, Goodwill Pharma aims to become the European gateway for East Asian pharmaceutical manufacturers, allocating its substantial retained earnings to accelerate international expansion.
Record Financial Results
Based on the 2025 financial statements approved by the Annual General Meeting, Goodwill Pharma achieved the following outstanding results in the most successful year of its nearly three-decade history:
Net consolidated revenue: Nearly HUF 23 billion, representing a dynamic 30% increase compared to the previous year
Strong profitability: EBITDA margin of 27.1% (HUF 6.2 billion), with a net profit margin of 17.4% (HUF 3.98 billion)
Shareholder value creation: The General Meeting approved a HUF 1 billion dividend, while significant retained earnings will finance further investments and expansion
“Building on the foundations laid over the past 28 years, we opened a new chapter last year: not only did we achieve record revenues, but we also significantly expanded our regional presence. In the coming period, we aim to further strengthen our position through proprietary developments and strategic partnerships. Our goal is to sustain the double-digit growth that has characterized our performance in recent years, alongside ongoing development initiatives,” said Dr. Ferenc Jójárt, Chairman and CEO of Goodwill Pharma Plc.
Expansion in the Balkans
A key contributor to the record profit was the company’s most significant strategic move to date: the Goodwill Group sold the distribution rights of the FORTACELL® product family in six Balkan countries to the STADA Group for HUF 4.18 billion.
The proceeds from the transaction will support the further development of the Group’s Serbian subsidiary, particularly in manufacturing and R&D capacities. This enables continued expansion of pharmaceutical and dietary supplement production launched in parallel in Szeged and Subotica, supported by new technologies and higher-capacity manufacturing equipment, further strengthening the company’s leading position in the Balkan region.
European Bridgehead for Asian Manufacturers Built in Szeged
Within the framework of the Hungarian Multi Program, Goodwill Pharma has completed a comprehensive investment program worth HUF 5.9 billion. The company has:
Commissioned a fully integrated, GMP-certified pharmaceutical manufacturing facility in Szeged (compliant with EU standards)
Established a new R&D and manufacturing laboratory
Tripled its logistics capacity
The project was financed through HUF 1.77 billion in government support, a HUF 2.75 billion credit facility, and HUF 1.38 billion in own resources (partly through capital raising).
The strategic value of this development lies in enabling the company to manufacture and package products in compliance with EU regulations, followed by approval from accredited authorities prior to market launch.
This positions Goodwill Pharma as a unique “one-stop-shop” entry point and European bridge partner for non-European—particularly East Asian—pharmaceutical manufacturers seeking access to EU markets.
Interest in the Szeged-based company has already emerged from Turkey, India, and China. Among its most significant partners is Techdow Pharmaceutical Co., Ltd., a global pharmaceutical company with approximately 2,150 employees and consolidated sales of around HUF 240 billion, which has entrusted Goodwill Pharma with the exclusive distribution of a biologically significant therapeutic product.
As a result of the capacity expansion, from 2026 onwards the company expects to launch more than 30 proprietary or in-licensed products annually across domestic and export markets.
Innovation Bridge Between East and West
With a workforce of over 300 employees and operations in 12 countries, Goodwill Pharma aims to serve as an innovation bridge between East and West.
In addition, through its “PharmaHub” model, the company is opening toward non-European biotech R&D partners, while implementing a science-based digital “megabrand” strategy supported by dynamic direct-to-consumer (D2C) online sales.
Further Information
István Tóth
Press Relations, Goodwill Pharma
M: +36 70 886 5476
Founded in 1997 and headquartered in Szeged, Goodwill Pharma Plc. has grown over the past 28 years into one of the fastest-growing pharmaceutical companies in Central and Eastern Europe, now present in 12 countries. Its outstanding innovation and business performance have been recognized with awards including Superbrands and the University of Szeged Alma Mater Prestige Award.
The company received the K&H Family Business Excellence Award in 2021 and the Deloitte Best Managed Companies Award in 2025.
Listed in the Standard category of the Budapest Stock Exchange and founder of the prestigious Albert Szent-Györgyi Medical Award, Goodwill Pharma employs more than 300 people. The company aims to introduce over 30 new products annually from 2026, continuously increasing shareholder value.
Further information: https://goodwillpharma.com/hu/
Shareholder and Investor Information
The total share capital of Goodwill Pharma Plc. amounts to HUF 1,071,764,450, consisting of 107,175,445 ordinary shares.
Annual reports and General Meeting resolutions are available in detail on the company’s investor relations website.